STOCK TITAN

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated news page for Cellectis (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellectis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellectis's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
acquisition
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
acquisition
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

190.14M
33.22M
12.13%
18.81%
0.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
France
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.